Development of meningitis during cephalothin therapy.
D000328:Adult; D000368:Aged; D001812:Blood-Brain Barrier; D002512:Cephalothin / Q000009:adverse effects* / Q000627:therapeutic use; D002764:Cholecystitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007710:Klebsiella Infections / Q000209:etiology; D008297:Male; D008581:Meningitis / Q000209:etiology*; D008584:Meningitis, Listeria / Q000209:etiology; D008585:Meningitis, Meningococcal / Q000209:etiology; D008586:Meningitis, Pneumococcal / Q000209:etiology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy
D002512:Cephalothin